Showing results (21-30 of 52) with videos related to
Sort By:
Pageof 6
Cancer|September 24, 2010
A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006Joel Picus, Susan Halabi, W Kevin Kelly, et al.Cancer|June 20, 2007
Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisoneJonathan E Rosenberg, Vivian K Weinberg, W Kevin Kelly, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2014
Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancerSusan Halabi, Chen-Yen Lin, W Kevin Kelly, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2008
Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancerMatthew D Galsky, Mario Eisenberger, Sandra Moore-Cooper, et al.The Lancet. Oncology|October 19, 2007
Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient dataKarim Fizazi, Aurelie Le Maitre, Gary Hudes, et al.Cancer|October 30, 2003
Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinomaDavid B Solit, Michael Morris, Susan Slovin, et al.BJU International|February 21, 2014
Long-term oncological outcomes of a phase II trial of neoadjuvant chemohormonal therapy followed by radical prostatectomy for patients with clinically localised, high-risk prostate cancerJonathan L Silberstein, Stephen A Poon, Daniel D Sjoberg, et al.Clinical Genitourinary Cancer|October 1, 2008
A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004Nancy A Dawson, Susan Halabi, San-San Ou, et al.Clinical Prostate Cancer|January 8, 2005
Preliminary assessment of magnetic resonance spectroscopic imaging in predicting treatment outcome in patients with prostate cancer at high risk for relapseDarko Pucar, Jason A Koutcher, Ankoor Shah, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapyMichael J Morris, Timothy Akhurst, Steven M Larson, et al.Pageof 6